Deficits in the German innovation landscape
The paper outlines the gaps between aspiration and reality using BioNTech as an example: Research has been going on into the exciting mRNA technology for a long time, partly privately financed, partly publicly. The fact that such a useful vaccine became available at such short notice was also a consequence of the need in the pandemic - which led to a joint effort by science, business and politics. In the everyday life of researchers who might be able to create something similarly useful, however, such acts of strength are rare. "In fact, BioNTech is an exceptional example - and thus refers to deficits in the normal operation of the German science and innovation landscape", so the paper.The spirit of research must not be restricted
Critics say: Normally, the state would have bought the Chinese vaccine instead of BioNTech.
Germany will be the magnet for Lithuanian scientific talents for a long time.